SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

Table 2 Results of planned meta-analyses with random effects

Outcome	Trials (n)	Estimate (HR)	95% CI	P value of HR	I² (%)	P value of I²
CV death and HFH
All	11	0.77	0.73–0.82	< 0.001	26.0	0.20
T2D: yes	4	0.74	0.64–0.84	< 0.001	0	0.81
T2D: no	4	0.77	0.64–0.91	< 0.001	0	0.72
Age > 65 years	3	0.75	0.66–0.84	< 0.001	0	0.92
Age ≤ 65 years	3	0.78	0.68–0.88	< 0.001	2.0	0.87
CV mortality
All	11	0.84	0.73–0.95	0.007	42.0	0.10
Total mortality
All	11	0.87	0.74–0.98	0.009	45.0	0.07
HF hospitalization
All	10	0.68	0.62–0.74	< 0.001	0	0.98
Kidney outcomes
All	10	0.65	0.56–0.75	< 0.001	35.0	0.10
MACE
All	6	0.88	0.83–0.93	< 0.010	21.2	0.19
Prior CVD	5	0.87	0.82–0.92	0.001	12.0	0.35
No prior CVD	3	0.93	0.83–1.07	0.326	55.1	0.10

CV, cardiovascular; HFH, hospitalization for heart failure; HR, hazard ratio; CI, confidence intervals; T2D, type 2 diabetes; MACE, major cardiovascular events

ISSN: 1475-2840